Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Adagene Starts US Trial of Lead Molecule; Also Approved for China Trials

publication date: Nov 1, 2018

Adagene, a Suzhou biopharma, has dosed the first patient in a US Phase I trial of its lead candidate, ADG-106, a fully human mAb targeting a novel epitope of CD137. At the same time, Adagene announced that China has approved an IND for ADG-106. The Phase I trial will test the drug as a single agent in patients with solid tumors and non-Hodgkin lymphoma. ADG-106 is the first Adagene candidate to begin clinical trials. In March of this year, Adagene raised $50 million in a Series C round to develop six oncology projects as they near clinical trials. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital